JP2024516183A5 - - Google Patents
Info
- Publication number
- JP2024516183A5 JP2024516183A5 JP2023565227A JP2023565227A JP2024516183A5 JP 2024516183 A5 JP2024516183 A5 JP 2024516183A5 JP 2023565227 A JP2023565227 A JP 2023565227A JP 2023565227 A JP2023565227 A JP 2023565227A JP 2024516183 A5 JP2024516183 A5 JP 2024516183A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- antisense oligonucleotide
- mrna
- sos1
- sos2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178420P | 2021-04-22 | 2021-04-22 | |
| US63/178,420 | 2021-04-22 | ||
| PCT/US2022/026052 WO2022226377A1 (en) | 2021-04-22 | 2022-04-22 | Compositions and methods for modulating sos gene expressions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516183A JP2024516183A (ja) | 2024-04-12 |
| JP2024516183A5 true JP2024516183A5 (https=) | 2025-04-30 |
Family
ID=83723199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565227A Pending JP2024516183A (ja) | 2021-04-22 | 2022-04-22 | Ｓｏｓ遺伝子発現を調節するための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240182894A1 (https=) |
| EP (1) | EP4326878A4 (https=) |
| JP (1) | JP2024516183A (https=) |
| KR (1) | KR20240032184A (https=) |
| CN (1) | CN117751190A (https=) |
| WO (1) | WO2022226377A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4396349A4 (en) * | 2021-09-02 | 2025-10-22 | Molecular Axiom Llc | COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION |
| CN119855910A (zh) | 2022-07-06 | 2025-04-18 | 美国微哲默理有限责任公司 | 用于治疗胰腺癌的组合物和方法 |
| WO2024138135A2 (en) * | 2022-12-22 | 2024-06-27 | Molecular Axiom, Llc | Compositions and methods for modulating sos gene expressions |
| WO2025111565A1 (en) * | 2023-11-22 | 2025-05-30 | Empirico Inc. | Treatment of sos2 related diseases and disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003256323A1 (en) * | 2002-06-26 | 2004-01-19 | Chiron Corporation | Sos1 inhibitors |
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| US7901882B2 (en) * | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| US20120021515A1 (en) * | 2009-02-06 | 2012-01-26 | Swayze Eric E | Oligomeric compounds and methods |
| US8802642B2 (en) * | 2010-04-28 | 2014-08-12 | Iowa State University Research Foundation, Inc. | Spinal muscular atrophy treatment via targeting SMN2 catalytic core |
| AU2014227824B2 (en) * | 2013-03-15 | 2018-09-27 | Dana-Farber Cancer Institute, Inc. | Stabilized SOS1 peptides |
| CA2954791C (en) * | 2014-07-14 | 2025-11-18 | The Regents Of The University Of California | CRISPR/CAS TRANSCRIPTIONAL MODULATION |
| US10676792B2 (en) * | 2015-04-01 | 2020-06-09 | The Regents Of The University Of California | Prognostic and diagnostic methods for colorectal cancer |
| EP3484524B1 (en) * | 2016-07-15 | 2022-11-09 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of smn2 |
| CN119855910A (zh) * | 2022-07-06 | 2025-04-18 | 美国微哲默理有限责任公司 | 用于治疗胰腺癌的组合物和方法 |
| WO2024138135A2 (en) * | 2022-12-22 | 2024-06-27 | Molecular Axiom, Llc | Compositions and methods for modulating sos gene expressions |
-
2022
- 2022-04-22 WO PCT/US2022/026052 patent/WO2022226377A1/en not_active Ceased
- 2022-04-22 EP EP22792624.3A patent/EP4326878A4/en active Pending
- 2022-04-22 CN CN202280044512.0A patent/CN117751190A/zh active Pending
- 2022-04-22 JP JP2023565227A patent/JP2024516183A/ja active Pending
- 2022-04-22 US US18/287,699 patent/US20240182894A1/en active Pending
- 2022-04-22 KR KR1020237040234A patent/KR20240032184A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516183A5 (https=) | ||
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| US6365345B1 (en) | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role | |
| US20160272970A1 (en) | RNA Interference Agents | |
| JP2021533804A5 (https=) | ||
| JPH09510714A (ja) | オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性 | |
| JP7384033B2 (ja) | 一本鎖オリゴヌクレオチド | |
| JP2023537798A5 (https=) | ||
| CN105121452A (zh) | 三环核苷和由其制备的寡聚化合物 | |
| EP4463553B1 (en) | Advanced rna targeting (arnatar) | |
| KR20020033744A (ko) | 사람 ｅｇ5의 발현을 억제하는 올리고뉴클레오티드 | |
| KR20200024793A (ko) | 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법 | |
| JP2024532477A5 (https=) | ||
| CN114369130B (zh) | 修饰的硫代寡核苷酸及其应用 | |
| JPWO2019044974A1 (ja) | スモールガイドアンチセンス核酸とその使用 | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| EP4562158A1 (en) | Advanced rna targeting (arnatar) for angiotensinogen | |
| JP2025501755A5 (https=) | ||
| JP2024535869A (ja) | Ｗｆｄｃ２の発現を調節するアンチセンス化合物 | |
| WO2021002359A1 (ja) | 核酸医薬とその使用 | |
| KR102613178B1 (ko) | Wfdc2의 발현을 조절하는 안티센스 화합물 | |
| HK40128552A (en) | Advanced rna targeting (arnatar) | |
| HK40118739B (en) | Advanced rna targeting (arnatar) | |
| HK40118739A (en) | Advanced rna targeting (arnatar) | |
| US20250250570A1 (en) | Translation enhancing nucleic acid compounds: aso coupled translation – upregulation 1 (act-up1) and uses thereof |